Key facts
- Notable investors include Jiahe Jinhui Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Changzhou Biotechnology Inc. Group
- ·The full record, as it builds
Funding rounds
No funding rounds for Changzhou Biotechnology Inc. Group are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Changzhou Biotechnology Inc. Group
Manufacturer of a therapeutic-vaccine & diagnostic-kit platform intended to advance treatments and detection of cervical cancer, tuberculosis and late-stage tumors. The company offers proprietary peptide-engineered immunotherapy products and in-house diagnostic reagents, enabling oncologists and infectious-disease specialists to deliver earlier immune evaluation and targeted disease intervention.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2012
- Employees
- 6
- Website
- vacmedix.cn/
- Ownership
- Privately Held (backing)
Changzhou Biotechnology Inc. Group doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Changzhou Biotechnology Inc. Group shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Changzhou Biotechnology Inc. Group in its N-PORT filings yet. We sweep new filings monthly.